. A decrease in muscle function in the elderly is not only directly linked to sarcopenia (a reduction in skeletal muscle mass owing to ageing) and to the prevalence of several chronic diseases, but also contributes enormously to overall quality of life, by diminishing strength, the ability to carry out daily tasks and social interactions, mobility, cognitive performance and life expectancy 7 . Even in the early elderly years, changes in physical activity have marked consequences for health status and life expectancy. For example, in one study, men of 70 years of age or older who engaged in exercise increased the probability that they would live until age 90 from 44% (for inactive men) to 54% (ref. 8) .
Increasing the amount of physical activity effectively prevents the development of many chronic diseases. Moreover, exercise is an excellent therapeutic intervention for conditions such as obesity, type 2 diabetes, neurodegeneration, osteoporosis and sarcopenia 1 . In terms of efficacy, exercise can be as beneficial as the drugs that are prescribed for many of these conditions (for example, for type 2 diabetes) 9 . The mechanisms that mediate the therapeutic effects of exercise and the pathological changes elicited by a sedentary lifestyle remain enigmatic. Here we propose a hypothesis for how inactivity, inflammation and chronic disease are linked at the molecular level, focusing on observations from human studies (except where noted).
Effects of inactivity on inflammation and chronic disease
Many chronic diseases are associated with sterile, persistent, low-grade inflammation ( Fig. 1 ). For example, the infiltration of immune cells into white adipose tissue, and therefore inflammation in this tissue, is closely correlated with the development of insulin resistance and type 2 diabetes 10 . Similarly, activated immune cells and inflammation have an important role in cardiovascular diseases, particularly in the aetiology of atherosclerosis 11, 12 . In addition, a systemic increase in the concentration of inflammatory cytokines stimulates the initiation of tumours, as well as their promotion and progression 13, 14 . Several neurodegenerative diseases are also linked to inflammation. These diseases are associated with a local inflammatory response in the brain, known as neuroinflammation. Neuroinflammation, for example, affects the activation of glial cells and the subsequent release of inflammatory cytokines such as tumour-necrosis factor-α (TNF-α). These cytokines are thought to promote the death of dopamine-containing neurons in the substantia nigra region of the brain, thereby contributing to the pathology of Parkinson's disease 15, 16 . Similarly, interleukin 1β (IL-1β), TNF-α-related apoptosis-inducing ligand (TRAIL) and other cytokines have been postulated to be involved in the aetiology of Alzheimer's disease 17 , as has amyloid-β, which itself has inflammatory effects 18 . It should be noted that in addition to the local inflammation found in many neurodegenerative diseases, systemic inflammation further exacerbates these diseases and promotes the progression of neuro degeneration 19 . Physical activity is tightly linked to inflammation and immunity in a complex manner 20 . Regular, moderate exercise reduces the level of systemic inflammation 21 . The mediators of this beneficial effect are unclear, but at least two distinct candidate mechanisms have been identified. First, exercise increases the release of adrenaline, cortisol, growth hormone, prolactin and other factors that have immunomodulatory effects 22 . Second, exercise results in decreased expression of Toll-like receptors at the surface of monocytes, which have been suggested to be involved in mediating systemic inflammation 23 . In contrast to the reduction of chronic inflammation that is afforded by regular, moderate exercise, high-intensity training for a prolonged period results in an increase in systemic inflammation and an increased risk of infection 21 . After such exercise, athletes undergo a transient exercise-induced immunodepression 24 . The recent discovery of myokines -that is, cytokines that are produced and secreted by skeletal muscle cells -sheds light on the association between exercise and inflammation 20 . The first myokine to be described was IL-6; other similar factors, including IL-8 (also known as CXCL8) and IL-15, are produced and secreted when muscle fibres . In addition to these myokines, more IL-1 receptor antagonist, IL-10 and TNF-α are found in the blood after exercise 25 . This change in TNF-α concentration is restricted to physical activity of extremely high intensity, so TNF-α might be the factor responsible for the heightened inflammatory state that occurs after prolonged, intense exercise.
After myokines have been released transiently into the circulation, they mediate some of the beneficial systemic effects of exercise on non-muscle tissues. IL-6, for example, modulates glucose production by the liver. Some of these myokines are clearly pro-inflammatory (for example, IL-1β and TNF-α) or anti-inflammatory (for example, IL-10 and IL-1 receptor antagonist). Paradoxically, other myokines have been reported to have both proinflammatory effects and anti-inflammatory effects 26 . For example, having a serum IL-6 concentration that is chronically higher than a standard basal concentration in healthy individuals is a predictor of developing obesity and type 2 diabetes. In addition, chronically increased concentrations of systemic IL-1β, IL-6, IL-8, IL-10 and TNF-α have been linked to the development of many diseases associated with inflammation, including cancer and other ageing-associated disorders, such as sarcopenia, neurodegeneration and depression 10, 11, 13, [27] [28] [29] . Finally, a chronic increase in IL-6 and TNF-α concentrations results in atrophy of skeletal muscle and inhibition of muscle regeneration, respectively 30, 31 . Thus, the transient fluctuations in local and systemic myokine concentrations after physical activity might contribute to the beneficial effects of exercise on non-muscle tissues in a hormone-like manner, whereas a chronic increase in the concentration of many of these molecules is likely to be pro-inflammatory and detrimental. It is clear therefore that the increase in IL-6 and other cytokines secreted by muscle during exercise, and the subsequent return of these cytokine concentrations to basal levels, is tightly regulated.
Endurance and strength training
Distinct exercise regimens are useful for preventing and treating different pathologies. Endurance training improves cardiovascular function 32 , whereas strength training reduces sarcopenia 33 . A combination of both training regimens has recently been reported to be the most beneficial for individuals with type 2 diabetes 34 . For preventing or treating other diseases, the optimal type of training remains to be defined. Interestingly, moderate exercise (such as walking) is sufficient to reduce the risk of developing dementia, as shown by a prospective study involving individuals of 65 years of age or older 35 . Strength training and endurance training activate distinct signal-transduction pathways and result in specific adaptations of skeletal muscle. The capacity of a muscle for adaptation depends mainly on the relative number and cross-sectional area of the different muscle-fibre types in a particular muscle 36 . Endurance improves with an increase in the number of type I and type IIA muscle fibres (as occurs during endurance training). Type I and type IIA muscle fibres are red in appearance and are characterized by a large number of mitochondria, more myoglobin and vascularization than type IIB and type IIX muscle fibres (which are the other main fibre types), and the presence of a specific set of myofibrillar proteins. These characteristics render the muscle fibres resistant to fatigue and enable them to contract slowly with a low peak force 37 . The main source of ATP for these fibres is oxidative phos phorylation of glucose and non-esterified fatty acids. By contrast, type IIB and type IIX muscle fibres appear white, have relatively few mitochondria and mainly metabolize phosphocreatine and glucose anaerobically to generate ATP. Both type IIB and type IIX muscle fibres are present in rodents, whereas humans have only type IIX muscle fibres. These fibres fatigue rapidly but can generate fast contractions with a high peak force 37 . When stimulated by strength training, type IIB and type IIX muscle fibres can undergo substantial hypertrophy 38 .
PGC1α and skeletal muscle physiology
The adaptation of muscle fibres to training is mediated by the firing patterns of their motor neurons 39 . These neurons initiate skeletal muscle contractions, through calcium signalling pathways. The gene-expression patterns that are specific to type I and type IIA muscle fibres are achieved by the frequent release of small amounts of calcium from the sarcoplasmic reticulum into the cytosol, as is observed during endurance training. Strength training, by contrast, results in the intermittent release of large amounts of calcium from the sarcoplasmic reticulum; this promotes the transcription of genes that mediate a type-IIBspecific and type-IIX-specific muscle-fibre response (that is, a contraction after a single burst of calcium and a change in fibre type after repeated bursts of calcium), as well as fibre hypertrophy 39 . With either type of training, the release of calcium from the sarcoplasmic reticulum activates the catalytic subunit of the protein phosphatase calcineurin and members of the calcium/calmodulin-dependent protein-kinase family, which together alter the phosphorylation state of multiple transcription factors and their coactivators 40 . This heightened calcium signalling activates several important transcription factors: cyclic-AMP-responsive-element-binding protein (CREB), myocyte-enhancer factor 2C (MEF2C) and MEF2D, and Inactivity is a risk factor for many chronic disorders, regardless of age, gender, race and health status. It also affects quality of life and life expectancy. Possible clinical consequences of inactivity are listed.
Metabolic conditions
Obesity, type 2 diabetes, dyslipidaemia (dysregulated lipid metabolism) and hypercholesterolaemia, metabolic syndrome and gallstone formation
Cardiovascular diseases
Hypertension, intermittent claudication (leg pain when walking but not when resting, angina, platelet adhesion and aggregation, atherosclerosis, thrombosis, coronary artery disease, myocardial infarction (heart attack), heart failure and stroke
Pulmonary diseases
Asthma and chronic obstructive pulmonary disease Cancers Breast cancer, colon cancer, endometrial cancer, prostate cancer, pancreatic cancer and melanoma
Neurological disorders
Learning and memory impairment, cognitive dysfunction, dementia, depression, mood and anxiety disorders and neurodegeneration (such as occurs in Alzheimer's disease, Huntington's disease and Parkinson's disease)
Musculoskeletal disorders
Lower-back pain, osteoporosis and related fractures, osteoarthritis and rheumatoid arthritis
Gastrointestinal conditions Reduced intestinal motility, and constipation
Immune-system alterations Immune dysfunction and chronic inflammation Sarcopenia Age-related muscle wasting Reduced quality of life Physical frailty, decreased psychological well-being, decreased ability to carry out daily tasks and social interactions, decreased functional independence, decreased mobility, increased susceptibility to psychological stress, impaired reaction skills, and impaired sense of balance, flexibility and agility
Shorter life expectancy
Box 1 | Clinical consequences of a sedentary lifestyle members of the nuclear factor of activated T cells (NFAT) family. These factors then alter the expression of exercise-regulated muscle genes, particularly the gene encoding the powerful transcriptional coactivator PGC1α (peroxisome-proliferator-activated receptor-γ (PPAR-γ) coactivator 1α) 41 . Accordingly, the expression of this gene, PGC1A (also known as PPARGC1A), is rapidly induced after a single bout of endurance exercise 42 . When physical activity stops, the amounts of PGC1A messenger RNA and PGC1α protein quickly revert to the quantities present before exercise 42 . During acute bouts of exercise, the increase in PGC1A expression is probably mainly a mechanism for modulating metabolic fluxes in skeletal muscle, in response to a decrease in ATP and altered fuel demands 43 . The multifaceted interaction of PGC1α with AMP-activated protein kinase is likely to be important for modulating these metabolic fluxes 44 : on activation, this protein kinase both phosphorylates PGC1α and induces the de novo synthesis of more PGC1α. In contrast to the transient increase in PGC1α that occurs during acute exercise, more PGC1α is present in chronically exercised skeletal muscle, even between individual bouts of exercise, than in untrained muscle 45 . This reflects the difference between short-term adaptation and long-term adaptation of skeletal muscle to endurance training.
Changes in muscle plasticity that are induced by chronic endurance exercise -such as fibre-type switching towards type I and type IIA muscle fibres, which are more oxidative and have greater endurance capacity than type IIB and type IIX muscle fibres -therefore cor relate with an increase in the basal expression of PGC1A 45 . Furthermore, even when muscle fibres are in a rested state, more PGC1α is present in oxidative (type I and type IIA) fibres than in glycolytic (type IIB and type IIX) fibres irrespective of whether the muscles are trained 46 . The role of PGC1α has been further confirmed by studies in transgenic mice. When a transgene encoding PGC1α is expressed in skeletal muscle at levels up to those observed in type I muscle fibres, there is a stable and robust fibre-type switch towards both type I and type IIA muscle fibres 46 . Individual muscle fibres from these mice are more resistant to fatigue than are fibres from wild-type mice, and these mice perform better at endurance exercise, indicating that the chronic increase in the amount of PGC1α mediates many (if not all) of the phenotypic changes observed in muscle that has undergone endurance training 46, 47 . The fibre switch promoted by PGC1α in these mice is characterized by an increase in mitochondrial density and function, an increase in oxidative metabolism, an increase in expression of myofibrillar proteins that are characteristic of type I and type IIA muscle fibres, and a switch in substrate fuel usage 46, 48 . Conversely, mice in which the gene encoding PGC1α has been selectively ablated in skeletal muscle (that is, musclespecific Pgc1a -/-mice) have more type IIB and type IIX (glycolytic) muscle fibres and a lower capacity for endurance exercise than wildtype mice 49 . From these studies, it is clear that PGC1α is a key mediator of many of the known beneficial effects of physical activity on skeletal muscle physiology 50, 51 .
PGC1α and chronic inflammation
One of the most important effects of exercise on human health is preventing protein catabolism and muscle wasting. These processes occur during limb immobilization, prolonged hospitalization, and various muscular dystrophies and other diseases. Therefore, changing the phenotypes of muscles in these patients to those of exercised muscles would improve the patients' health and overall quality of life, but these patients often cannot exercise effectively. Several studies indicate, however, that PGC1α prevents protein catabolism and muscle wasting in a variety of contexts. For example, denervation-induced muscle atrophy, muscle damage caused by treatment with statins, and the effects of Duchenne's muscular dystrophy are greatly ameliorated when the amount of PGC1α is maintained at normal levels or increased [52] [53] [54] . The precise mechanisms by which PGC1α mediates these beneficial effects are unclear, but there are several possibilities (Fig. 2) . Increasing the expression of mitochondrial genes and other metabolic genes, and the resultant correction of the 'energy crisis' that is associated with muscular dystrophies 44, 55 , is a plausible mechanism. Other factors that are likely to contribute to the protection against muscle wasting provided by PGC1α are a decrease in the transcription of atrophy-specific genes (by inhibiting the activity of the transcription factor forkhead box O3 (FOXO3)) 54 , an increase in the transcriptional program for protein synthesis 54, 56 , and stabilization of the postsynaptic side of the junction between the motor neuron and the muscle fibre (the neuromuscular junction) 53 . In particular, regulating the genes that encode the postsynaptic components of the neuromuscular junction could ameliorate the pathology of neuromuscular disorders in which this junction has a reduced function, even those in which aberrant motor neuron function, and not skeletal muscle dysfunction, is the primary cause.
A key observation that might be relevant to a much broader set of chronic disorders arose from detailed studies of the previously mentioned muscle-specific Pgc1a -/-mice 49, 57 . Many genes that are involved in local inflammation or systemic inflammation were transcribed in the muscles of these mice, particularly those encoding the inflammatory cytokines IL-6 and TNF-α, and suppressor of cytokine signalling 1 (SOCS1), SOCS3 and CD68 (refs 49, 57) . In addition, mice with skeletal muscle cells that were heterozygous for Pgc1a (Pgc1a +/-) showed a smaller, but significant, increase in the expression of many of these genes 57 . In both cases, a chronic increase in the amount of circulating IL-6 was observed 57 . Similarly, Pgc1a -/-primary muscle cells that had been differentiated into myotubes in vitro contained more Tnfa and Il6 mRNA and secreted more IL-6 into the culture medium than did wildtype myotubes 57 . Conversely, expression of Pgc1a from an adenoviral vector in myotubes derived from C2C12 cells (an immortalized mouse muscle cell line) reduced the amount of Tnfa and Il6 mRNA in vitro 57 . Taken together, these data strongly suggest that, after ablation of Pgc1a, at least some of the inflammatory cytokines that circulate in vivo originate from the skeletal muscle cells themselves, suggesting that PGC1α usually functions to suppress the production of such inflammatory mediators. Clearly, the transcriptional program by which muscle cells produce these cytokines might be amplified by the recruitment of particular immune cells, which can amplify an inflammatory response, to the muscle.
Importantly, mice with Pgc1a +/-skeletal muscle cells have a reduction in Pgc1a mRNA 57 that is quantitatively comparable to the transcriptional dysregulation (a 36% reduction) observed in the muscle of people with type 2 diabetes compared with healthy volunteers 58, 59 . Furthermore, this reduction in expression corresponds quantitatively to the reduction in Pgc1a mRNA observed in the muscles of sedentary mice compared with exercising mice 54 . Although it is not possible in humans to establish whether the link between reduced expression of PGC1α and the expression of inflammatory genes is causal, people with type 2 diabetes also have increased transcription of the genes encoding IL-6 and TNF-α in skeletal muscle, as well as an increased concentration of IL-6 in serum 57 . Thus, the reduction of PGC1A mRNA in the skeletal muscle of people with type 2 diabetes is likely to be closely linked to the chronic, low-grade inflammation that is present in these individuals. Finally, individuals with early-stage (preclinical) type 2 diabetes also have less skeletal muscle PGC1α than healthy volunteers, probably contributing to an increase in the systemic concentration of IL-6, a strong predictor that type 2 diabetes will develop 60 . Indeed, skeletal muscle PGC1α levels correlate inversely with expression of IL-6 and TNFA in individuals with normal glucose tolerance or type 2 diabetes 57 . Taken together, these findings strongly suggest that there is a causal relationship between the increases in PGC1α expression observed in human skeletal muscle after physical activity and the reduction in cytokine release from skeletal muscle that is known to occur with moderate exercise. Conversely, the effect on mice of losing even one Pgc1a allele, stimulating a broad program of cytokine expression and release, strongly suggests that a similar process occurs in humans who engage in chronic sedentary behaviour. For example, both muscle-specific Pgc1a -/-mice and individuals not engaging in adequate physical activity have a decreased capacity to exercise and a muscle-fibre-type switch towards glycolytic muscle fibres 49 . The molecular mechanisms that link PGC1α and inflammatory gene expression in muscle are unknown, but they might reflect the role of PGC1α in the control of reactive oxygen species (ROS). PGC1α is a powerful suppressor of ROS production, which it does in parallel with increasing mitochondrial respiration. This process occurs through the PGC1α-mediated expression of enzymes involved in ROS detoxification, as well as uncoupling proteins that can attenuate ROS production 61, 62 . In fact, increased oxidative stress and inflammation are known to go hand in hand in many skeletal-muscle-associated diseases 63 . Specifically, ROS have been shown to induce inflammatory cytokine production in skeletal muscle 64 . Thus, the decreased expression of the anti-ROS genes (that is, those encoding the ROS-detoxification enzymes and the uncoupling proteins) in muscle-specific Pgc1a -/-mice 57 is likely to make a substantial contribution to the observed increases in cytokine expression. Clearly, PGC1α might have other, more-direct, effects on the expression of genes whose products have pro-inflammatory or anti-inflammatory activity.
Analysis of muscle-specific Pgc1a -/-mice revealed that dysregulation of PGC1α in skeletal muscle does not cause insulin resistance in this tissue but causes abnormal systemic glucose and insulin homeostasis as a result of reduced insulin levels and abnormal pancreatic islet morphology. This unexpected effect at a distal site seems to result from a harmful cross-talk between skeletal muscle and pancreatic β-cells in these animals 57 . An increase in systemic inflammation is one likely mechanism by which skeletal muscle with dysregulated expression of the gene encoding PGC1α could modulate β-cell function: the concentration of IL-6 in the blood of muscle-specific Pgc1a -/-mice increases concomitant with a reduction in insulin secretion by β-cells 57 . Similarly, in isolated islets in vitro, glucose-stimulated insulin secretion by β-cells is reduced in response to IL-6 in both wild-type mice and muscle-specific Pgc1a -/-mice 57 . These data indicate unambiguously that the amount of skeletal muscle PGC1α can markedly affect the function of pancreatic islets. Given this effect, skeletal muscle PGC1α levels probably influence the structure and functions of other tissues and organs as well.
Systemic effects of exercise and PGC1α
We suggest here that the decrease in PGC1A expression in skeletal muscle that results from sedentary behaviour can elicit a low-level chronic inflammatory response, which has a negative impact on many other tissues. As noted earlier, many (if not all) chronic diseases of ageing -including cardiovascular disease, cancer and neurodegeneration -are associated with chronic inflammation. In many cases, this association has been shown to be causal in defined experimental systems. Suppressing chronic inflammation in muscle through the exercise-mediated induction of PGC1A expression would be expected to lower the frequency and/or severity of these diseases. In terms of clinical data, exercise has many neurological benefits, most notably improved learning and memory, protection against neurodegeneration, and amelioration of depression and other mood disorders 18 . Cancer of the colon, breast, prostate, endometrium, pancreas and skin all have a greater incidence in inactive individuals than in those who exercise 1, 65 . Thus, multi-organ health and plasticity as a result of exercise might be strongly affected by altering the level of systemic inflammation through controlling the amount and activity of PGC1α in skeletal muscle.
It is important to note that it is unlikely that any of the chronic diseases discussed here are caused by a reduction in PGC1α alone. Instead, these diseases are multifactorial: that is, several 'insults' are required for a chronic disease to fully develop. The multifactorial nature of human cancer is a useful conceptual model for most chronic diseases. The multiple insults required might originate from the genetic heritage of a patient, be acquired as a result of spontaneous somatic mutations, and/or result from environmental or lifestyle factors. Thus, variables such as sedentary behaviour and reduced amounts of skeletal muscle PGC1α could be viewed, on a population basis, as shifting the likelihood of developing disease compared with individuals who engage in the recommended amount of exercise or physical activity (http://www.cdc.gov/nccdphp/ dnpa/physical/everyone/recommendations/index.htm) (Fig. 3) . For any given individual, it is difficult to determine the impact of sedentary behaviour on the risk of developing a particular disease. But it is clear that widespread sedentary behaviour has an impact on the population overall. Conversely, populations with above-average physical activity and thus more skeletal muscle PGC1α have a lower incidence of disease than those with average activity and therefore average amounts of skeletal muscle PGC1α.
Obesity and inactivity
Sedentary behaviour often contributes to the development of obesity and is often concurrent with obesity 1, 66, 67 . Conversely, individuals who are obese are less likely to exercise 66, 67 . Inactivity and obesity are also independent risk factors for many of the same chronic diseases. In fact, inactivity increases the risk of developing chronic diseases irrespective of body mass index (a measure of obesity). Thus, as an independent risk factor, inadequate physical activity exacerbates the detrimental effects of obesity 1 . We predict that lack of exercise and obesity interact to have a harmful effect on the transcriptional programs discussed here.
Obesity has been strongly associated with an inflammatory transcriptional program, which includes the expression of genes encoding TNF-α, IL-1β and IL-6 (ref. 10). More precisely, it has been known for more than a decade that adipose tissue, in the context of obesity, secretes increased amounts of these cytokines in both rodents and humans 68, 69 . More over, TNF-α and other adipokines (cytokines produced by adipocytes) have been shown to have a functional role in the insulin resistance that is observed in obese mice 10 . If it is assumed that there is a quantitative threshold of systemic cytokines that needs to be present chronically for pathology to occur in other tissues (that is, non-adipose and nonmuscle tissues), then this threshold is much more likely to be reached in individuals who are both inactive and obese than in those who are just inactive (Fig. 3) . Furthermore, if the age of onset of a particular disease or the extent of disease is dose responsive with respect to the concentrations of systemic inflammatory molecules, then sedentary behaviour coupled with obesity would be expected to bring about disease earlier and/or in a more severe form 70 . Obesity and sedentary behaviour might also interact in ways that are not just quantitative. Complete lists of the cytokines that contribute to the onset of particular diseases are not yet known, but obesity and sedentary behaviour might bring together a particular combination of adipokines and myokines that function additively or even synergistically to cause disease. But how large are the possible synergistic effects of obesity and sedentary behaviour in humans? Similar to other modifiable factors -such as smoking, type 2 diabetes and hypertension -obesity is predicted to reduce an individual's life expectancy by 1-5 years. By contrast, physical activity is estimated to increase it by up to 5 years. Importantly, a composite lifestyle of healthy behaviours -for example, engaging in sufficient exercise while having a healthy diet -has been proposed to add 10 years to the average life expectancy 8, 71 .
Testing the hypothesis
It is clear from the findings presented here that many aspects of the physiological and pathophysiological effects of modulating PGC1α in skeletal muscle and other organs remain enigmatic. Even less is known about the functions and therapeutic potential of the other two members of this gene family: the genes encoding PGC1β and PGC1-related coactivator (PRC). Similar to PGC1α, transgenic expression of PGC1β in skeletal muscle increases the capacity of mice for endurance exercise in comparison to wild-type mice; however, different mechanisms seem to control the PGC1α-and PGC1β-mediated increases in endurance 72 . In the future, altering the amount and/or activity of PGC1α in skeletal muscle might be a useful way to prevent and treat certain diseases. The effects of musculoskeletal disorders -disuse-induced muscle atrophy 54 , Duchenne's muscular dystrophy 53 and statin-mediated muscle wasting 52 -have already been ameliorated by altering PGC1α in this manner in experimental animal models. The potential of skeletal muscle PGC1α to modulate non-muscular diseases has not yet been studied, but the ideas that we have presented are readily testable in experimental animal models. For example, we propose that mice lacking one or both copies of Pgc1a in skeletal muscle are more susceptible to cancers, cardio vascular disease and neurological disorders. To test this idea, mice lacking Pgc1a could be treated with chemical carcinogens that cause cancer of the breast, colon or other tissues, and the rate of tumour formation and progression could be determined quantitatively. Similarly, these mice could be given challenges that induce heart failure or certain types of neurodegeneration that model Parkinson's disease or Alzheimer's disease, and the rates of incidence and progression could be monitored.
To improve human health, it will be important to determine appropriate exercise regimens that will protect against diseases associated with muscle-based inflammation. But chemical modulation of the PGC1α pathway in skeletal muscle could also have a huge impact in the clinic. Drugs and drug-like compounds have been shown to modulate the expression of Pgc1a in mouse muscle cells in vitro 56, 73, 74 . In addition, several of the transcription factors that bind to PGC1α and thus regulate transcription in skeletal muscle have been identified 50, 51 and could be therapeutic targets. For example, when PGC1α is recruited by the transcription factor oestrogen-related receptor-α, the mitochondrial genes involved in oxidative phosphorylation are transcribed, and these genes are dysregulated in the muscle of people with type 2 diabetes 56 . Pharmacological disruption of the interaction between these two proteins in cultured muscle cells induces a metabolic phenotype resembling that of in vivo muscle in an individual with type 2 diabetes 56 . These findings point to how PGC1α could be targeted selectively 75 , an important consideration if PGC1α is to be modulated in the clinic. If successful, therapeutic modulation of PGC1α has a huge potential for the treatment of patients with muscle wasting, sarcopenia, type 2 diabetes and muscular dystrophies, as well as other serious non-muscular chronic diseases. 
